Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ImmunoGen, Inc. | SVP & CHIEF COMMERCIAL OFFICER | Restricted Stock Unit | 50K | $1.47M | $29.40 | Nov 15, 2022 | Direct |
ImmunoGen, Inc. | SVP & CHIEF COMMERCIAL OFFICER | Common Stock | 25K | $741K | $29.64 | Nov 15, 2022 | Direct |
eFFECTOR Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 800 | Jun 13, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
EFTR | eFFECTOR Therapeutics, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 13, 2024 | Director |
EFTR | eFFECTOR Therapeutics, Inc. | Feb 19, 2024 | 1 | $0 | 4 | Feb 21, 2024 | Director |
EFTR | eFFECTOR Therapeutics, Inc. | Jun 22, 2023 | 1 | $0 | 4 | Jun 22, 2023 | Director |
EFTR | eFFECTOR Therapeutics, Inc. | Jan 20, 2023 | 1 | $0 | 4 | Jan 24, 2023 | Director |
IMGN | ImmunoGen, Inc. | Nov 15, 2022 | 2 | $0 | 4 | Nov 18, 2022 | SVP & CHIEF COMMERCIAL OFFICER |
EFTR | eFFECTOR Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 13, 2022 | Director |
EFTR | eFFECTOR Therapeutics, Inc. | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Director |
EFTR | eFFECTOR Therapeutics, Inc. | Feb 15, 2022 | 0 | $0 | 3 | Feb 17, 2022 | Director |
IMGN | ImmunoGen, Inc. | Nov 15, 2021 | 2 | $2.56M | 4 | Nov 17, 2021 | SVP & Chief Commercial Officer |
IMGN | ImmunoGen, Inc. | Nov 15, 2021 | 0 | $0 | 3 | Nov 17, 2021 | SVP & Chief Commercial Officer |